Literature DB >> 18785973

Attenuation of monocyte proinflammatory cytokine responses to Neisseria meningitidis in children by erythropoietin.

C Schultz1, J Zimmer, C Härtel, J Rupp, P Temming, T Strunk.   

Abstract

Meningococcal disease is a leading infectious cause of death in children in industrialized countries. The induction of high levels of proinflammatory cytokines has been implicated in the pathogenesis of Neisseria meningitidis-related multi-organ failure. Here, we demonstrate that N. meningitidis serotypes A and B induce significantly higher levels of tumour necrosis factor (TNF)-alpha positive cells in vitro in infants and young children compared with adults (serotype A/B; infants: 64.9%/63.9%; children: 77.8%/64.3% versus adults: 27.7%/32%; P < 0.005). Serotype A induces also higher levels of interleukin (IL)-6 positive cells in neonates and infants compared with adults (serotype A; newborn 55.4%; infants 58.8% versus adults 49%; P < 0.05). Treatment with human recombinant erythropoietin in vitro resulted in significant attenuation of the N. meningitidis-induced proinflammatory response in all age groups (reduction rate of erythropoietin for IL-6 after stimulation with serotype B: newborn 28%, infants 15%, children 23% and adults 28% and for TNF-alpha after stimulation with serotype B: newborn 27%, infants 22%, children 20% and adults 28%; P < 0.05). We conclude that (i) Neisseria meningitidis induces a higher TNF-alpha response in infants and children compared with adults and (ii) erythropoietin was able to attenuate IL-6 and TNF-alpha production in all investigated age groups. These data may explain the high incidence of meningococcal infection in infants and makes erythropoietin a potentially attractive candidate for interventional strategies in an otherwise devastating course of the disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18785973      PMCID: PMC2612721          DOI: 10.1111/j.1365-2249.2008.03760.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  15 in total

1.  Neonatal inflammatory response.

Authors:  Jörg Dembinski; Daniela Behrendt; P Bartmann
Journal:  Pediatr Res       Date:  2003-05       Impact factor: 3.756

2.  Immature anti-inflammatory response in neonates.

Authors:  C Schultz; P Temming; P Bucsky; W Göpel; T Strunk; C Härtel
Journal:  Clin Exp Immunol       Date:  2004-01       Impact factor: 4.330

3.  Erythropoietin therapy for acute stroke is both safe and beneficial.

Authors:  Hannelore Ehrenreich; Martin Hasselblatt; Christoph Dembowski; Lukas Cepek; Piotr Lewczuk; Michael Stiefel; Hans-Heino Rustenbeck; Norbert Breiter; Sonja Jacob; Friederike Knerlich; Matthias Bohn; Wolfgang Poser; Eckart Rüther; Michael Kochen; Olaf Gefeller; Christoph Gleiter; Thomas C Wessel; Marc De Ryck; Loretta Itri; Hilmar Prange; Anthony Cerami; Michael Brines; Anna-Leena Sirén
Journal:  Mol Med       Date:  2002-08       Impact factor: 6.354

4.  Release of tumor necrosis factor: an innate host characteristic that may contribute to the outcome of meningococcal disease.

Authors:  R G Westendorp; J A Langermans; C E de Bel; A E Meinders; J P Vandenbroucke; R van Furth; J T van Dissel
Journal:  J Infect Dis       Date:  1995-04       Impact factor: 5.226

5.  Role of interleukin 6 in myocardial dysfunction of meningococcal septic shock.

Authors:  Nazima Pathan; Cheryl A Hemingway; Ash A Alizadeh; Alick C Stephens; Jennifer C Boldrick; Emmanuelle E Oragui; Colm McCabe; Steven B Welch; Adeline Whitney; Peter O'Gara; Simon Nadel; David A Relman; Sian E Harding; Michael Levin
Journal:  Lancet       Date:  2004-01-17       Impact factor: 79.321

6.  Early treatment with erythropoietin beta ameliorates anemia and reduces transfusion requirements in infants with birth weights below 1000 g.

Authors:  Rolf F Maier; Michael Obladen; Ingo Müller-Hansen; Evelyn Kattner; Ulrich Merz; Romaine Arlettaz; Peter Groneck; Hannes Hammer; Hans Kössel; Gaston Verellen; Gerd-Jürgen Stock; Thierry Lacaze-Masmonteil; Olivier Claris; Martin Wagner; Jacqueline Matis; Frank Gilberg
Journal:  J Pediatr       Date:  2002-07       Impact factor: 4.406

7.  Downregulation of proinflammatory cytokine release in whole blood from septic patients.

Authors:  W Ertel; J P Kremer; J Kenney; U Steckholzer; D Jarrar; O Trentz; F W Schildberg
Journal:  Blood       Date:  1995-03-01       Impact factor: 22.113

Review 8.  Does erythropoietin protect the preterm brain?

Authors:  T Strunk; C Härtel; C Schultz
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2004-07       Impact factor: 5.747

9.  Erythropoietin inhibits cytokine production of neonatal and adult leukocytes.

Authors:  Tobias Strunk; Christoph Härtel; Petra Temming; Nadja Matzke; Janna Zimmer; Christian Schultz
Journal:  Acta Paediatr       Date:  2007-12-03       Impact factor: 2.299

10.  Characterization of humoral and cellular immune responses elicited by meningococcal carriage.

Authors:  K Robinson; K R Neal; C Howard; J Stockton; K Atkinson; E Scarth; J Moran; A Robins; I Todd; E Kaczmarski; S Gray; I Muscat; R Slack; D A A Ala'Aldeen
Journal:  Infect Immun       Date:  2002-03       Impact factor: 3.441

View more
  3 in total

1.  Effect of low-dose ketamine on post-operative serum IL-6 production among elective surgical patients: a randomized clinical trial.

Authors:  Tonny Stone Luggya; Tony Roche; Lameck Ssemogerere; Andrew Kintu; John Mark Kasumba; Arthur Kwizera; Jose Vb Tindimwebwa
Journal:  Afr Health Sci       Date:  2017-06       Impact factor: 0.927

2.  Elevated endogenous erythropoietin concentrations are associated with increased risk of brain damage in extremely preterm neonates.

Authors:  Steven J Korzeniewski; Elizabeth Allred; J Wells Logan; Raina N Fichorova; Stephen Engelke; Karl C K Kuban; T Michael O'Shea; Nigel Paneth; Mari Holm; Olaf Dammann; Alan Leviton
Journal:  PLoS One       Date:  2015-03-20       Impact factor: 3.240

3.  A multi-center study on the regenerative effects of erythropoietin in burn and scalding injuries: study protocol for a randomized controlled trial.

Authors:  Christina Irene Günter; Augustinus Bader; Ulf Dornseifer; Silvia Egert; Sebastian Dunda; Gerrit Grieb; Thomas Wolter; Norbert Pallua; Tobias von Wild; Frank Siemers; Peter Mailänder; Oliver Thamm; Carsten Ernert; Michael Steen; Reiner Sievers; Bert Reichert; Afshin Rahmanian-Schwarz; Hans Schaller; Bernd Hartmann; Max Otte; Victoria Kehl; Christian Ohmann; Wolfgang Jelkmann; Hans-Günther Machens
Journal:  Trials       Date:  2013-05-03       Impact factor: 2.279

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.